CA3177117A1 - Substituted benzotriazinone metabolites of a gpr139 agonist - Google Patents
Substituted benzotriazinone metabolites of a gpr139 agonist Download PDFInfo
- Publication number
- CA3177117A1 CA3177117A1 CA3177117A CA3177117A CA3177117A1 CA 3177117 A1 CA3177117 A1 CA 3177117A1 CA 3177117 A CA3177117 A CA 3177117A CA 3177117 A CA3177117 A CA 3177117A CA 3177117 A1 CA3177117 A1 CA 3177117A1
- Authority
- CA
- Canada
- Prior art keywords
- oxo
- trifluoromethoxy
- ethyl
- triazin
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C201/00—Preparation of esters of nitric or nitrous acid or of compounds containing nitro or nitroso groups bound to a carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063021895P | 2020-05-08 | 2020-05-08 | |
| US63/021,895 | 2020-05-08 | ||
| PCT/IB2021/000304 WO2021224680A1 (en) | 2020-05-08 | 2021-05-06 | Substituted benzotriazinone metabolites of a gpr139 agonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3177117A1 true CA3177117A1 (en) | 2021-11-11 |
Family
ID=76624075
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3177117A Pending CA3177117A1 (en) | 2020-05-08 | 2021-05-06 | Substituted benzotriazinone metabolites of a gpr139 agonist |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US12559465B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4146635A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7697974B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3177117A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021224680A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI873185B (zh) | 2019-09-16 | 2025-02-21 | 日商武田藥品工業股份有限公司 | 唑稠合之嗒-3(2h)-酮衍生物 |
| JP7697974B2 (ja) | 2020-05-08 | 2025-06-24 | 武田薬品工業株式会社 | Gpr139アゴニストの置換ベンゾトリアジノン代謝物 |
| CN116693545A (zh) * | 2022-03-01 | 2023-09-05 | 上海科技大学 | 噻吩并含氮杂环类化合物、含其的药物组合物、其制备方法及其应用 |
| CN116693536A (zh) * | 2022-03-01 | 2023-09-05 | 上海科技大学 | 吡咯并三嗪酮类化合物、含其的药物组合物、其制备方法及其应用 |
| CN121159462A (zh) * | 2025-11-19 | 2025-12-19 | 杭州市第七人民医院(杭州市心理危机研究与干预中心) | 喹唑啉酮类化合物及其在制备神经系统疾病药物中的应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3794726A (en) | 1972-08-21 | 1974-02-26 | Uniroyal Inc | Inhibiting aggressive behavior with 1,2,3-benzotriazin-(3h)-one |
| ATE108791T1 (de) | 1987-11-04 | 1994-08-15 | Beecham Group Plc | Neue 4-oxobenzotriazine und 4-oxochinazoline. |
| JP4079727B2 (ja) | 2002-09-06 | 2008-04-23 | セントラル硝子株式会社 | 光学活性1−(フルオロ、トリフルオロメチルまたはトリフルオロメトキシ置換フェニル)アルキルアミンn−モノアルキル誘導体とその製造方法 |
| CA2526506A1 (en) | 2003-06-09 | 2004-12-16 | Boehringer Ingelheim International Gmbh | Inhibitors of papilloma virus |
| EP1651643A4 (en) | 2003-07-31 | 2008-10-08 | Irm Llc | BICYCLIC COMPOUNDS AND COMPOSITIONS USED AS PDF INHIBITORS |
| FR2875805B1 (fr) | 2004-09-27 | 2006-12-29 | Genfit S A | Composes derives de n-(benzyl) phenylacetamide substitues, preparation et utilisations |
| UY30048A1 (es) | 2005-12-23 | 2007-07-31 | Astrazeneca Ab | Derivados sustituidos de la n,2-(1h-benzimidazol-1-il) acetamida, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones |
| TWI433839B (zh) | 2006-08-11 | 2014-04-11 | Neomed Inst | 新穎的苯并咪唑衍生物290 |
| AU2008345225A1 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| WO2011138265A2 (en) | 2010-05-03 | 2011-11-10 | Evotec Ag | Indole and indazole derivatives as orexin receptor antagonists |
| EP2968240A2 (en) | 2013-03-14 | 2016-01-20 | Janssen Pharmaceutica, N.V. | Physiological ligands for gpr139 |
| JO3719B1 (ar) | 2014-11-20 | 2021-01-31 | Takeda Pharmaceuticals Co | 4- أوكسو-4،3- داي هيدرو-3،2،1- بنزوترايازينات كمواد ضابطة لأجل gpr139 |
| TWI873185B (zh) | 2019-09-16 | 2025-02-21 | 日商武田藥品工業股份有限公司 | 唑稠合之嗒-3(2h)-酮衍生物 |
| JP7697974B2 (ja) | 2020-05-08 | 2025-06-24 | 武田薬品工業株式会社 | Gpr139アゴニストの置換ベンゾトリアジノン代謝物 |
| US20230310441A1 (en) | 2020-09-21 | 2023-10-05 | Takeda Pharmaceutical Company | Treatment for schizophrenia |
-
2021
- 2021-05-06 JP JP2022567286A patent/JP7697974B2/ja active Active
- 2021-05-06 WO PCT/IB2021/000304 patent/WO2021224680A1/en not_active Ceased
- 2021-05-06 US US17/998,131 patent/US12559465B2/en active Active
- 2021-05-06 EP EP21734917.4A patent/EP4146635A1/en active Pending
- 2021-05-06 CA CA3177117A patent/CA3177117A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021224680A8 (en) | 2023-01-05 |
| US12559465B2 (en) | 2026-02-24 |
| WO2021224680A1 (en) | 2021-11-11 |
| US20230227416A1 (en) | 2023-07-20 |
| JP2023524133A (ja) | 2023-06-08 |
| JP7697974B2 (ja) | 2025-06-24 |
| EP4146635A1 (en) | 2023-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109988109B (zh) | 抑制ssao/vap-1的胺类化合物及其用途 | |
| US12559465B2 (en) | Substituted benzotriazinone metabolites of a GPR139 agonist | |
| CA3119656A1 (en) | Macrocyclic compounds and their use in the treatment of disease | |
| CA3149963A1 (en) | Heterocyclic rip1 kinase inhibitors | |
| CN102307868B (zh) | 作为抗癌剂的吲哚衍生物 | |
| CN113825754B (zh) | 包括甲基和三氟甲基的双取代磺酰胺类选择性bcl-2抑制剂 | |
| CN110177788A (zh) | 作为bcl-2选择性凋亡诱导剂的化合物 | |
| CA2939081A1 (en) | Cyclopropylamines as lsd1 inhibitors | |
| EP3105219A1 (en) | Cyclopropylamines as lsd1 inhibitors | |
| EP3143020A1 (en) | Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection | |
| EP1870405A1 (en) | Carbonylated (Aza)cyclohexanes as dopamine D3 receptor ligands | |
| WO2014137723A1 (en) | Compounds inhibiting leucine-rich repeat kinase enzyme activity | |
| BR112017002811B1 (pt) | Compostos de pirrolopirimidina usados como agonista de tlr7 e seu uso, composição farmacêutica e kit | |
| TW201625305A (zh) | 用於癌症治療之組合療法 | |
| NZ721723A (en) | Tetrahydropyridopyrazines modulators of gpr6 | |
| EP3640248B1 (en) | Aminopyrimidine derivatives, preparation method therefor and use thereof | |
| CN104854101A (zh) | Alk激酶抑制剂 | |
| CN107459476B (zh) | 反吲哚啉环丙胺类化合物及其制备方法、药物组合物和用途 | |
| CA3094481A1 (en) | Phenothiazine derivatives and uses thereof | |
| WO2025026392A1 (zh) | 驱动蛋白kif18a抑制剂及其应用 | |
| US20070088021A1 (en) | 4-haloisoquinoline derivative and drug containing the same | |
| CN106414443B (zh) | 吡啶并嘧啶二酮衍生物 | |
| WO2023280290A1 (zh) | 一种吡咯磺酰类衍生物、及其制备方法与应用 | |
| CN111108083A (zh) | 氨基亚甲基环己烷1,3-二酮化合物的用途 | |
| CN104334561A (zh) | 化合物jk12a及其制备 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250424 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250424 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250501 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250501 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250501 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250714 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250714 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250714 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250714 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260309 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260617 |